Browse the corpus

Cromolyn sodium is a mast cell stabilizer derived from khellin, a natural extract from the herb Ammi visnaga, first introduced as an inhaled treatment for asthma in 1969. Cromolyn sodium prevents the release of inflammatory mediators like histamine and leukotrienes, helping to manage asthma, allergic rhinitis, mastocytosis, and certain allergic eye conditions. In some patients, cromolyn sodium improves symptoms of diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. This medication is not effective for acute asthma attacks but is used prophylactically. Available in various forms, including oral, nasal, and ophthalmic solutions, cromolyn sodium is FDA-approved for asthma prophylaxis, allergic rhinitis, and mast cell diseases, with off-label uses for food allergies and inflammatory bowel disease. This activity for healthcare professionals is designed to enhance the learner's competence in prescribing cromolyn sodium effectively and implementing an appropriate interprofessional management approach in patients treated with this medication to improve outcomes. Objectives: Differentiate cromolyn sodium from other asthma and allergy treatments, understanding its unique mechanism as a mast cell stabilizer. Screen for potential allergic or adverse reactions associated with cromolyn sodium to ensure safe and effective treatment. Implement evidence-based guidelines for the prophylactic use of cromolyn sodium in patients with asthma and mast cell disorders. Apply interprofessional team strategies to improve care coordination and outcomes in patients treated with cromolyn sodium. Access free multiple choice questions on this topic.

Cromolyn sodium is poorly absorbed and is low in toxicity. No severe toxicity reactions have been reported, and a specific toxic dose has not been established. Research verifying the efficacy or safety of cromolyn sodium is insufficient regarding use in pediatric patients younger than 2 years. However, acute life-threatening reactions have been reported. In the event of a hypersensitivity reaction, patients should receive treatment with antihistamines with or without beta-agonists, corticosteroids, and epinephrine. In the case of a severe hypersensitivity reaction, oxygen, antihistamines, epinephrine, corticosteroids, electroencephalogram monitoring, and intravenous fluids should be administered. No specific labs or testing are necessary unless indicated.[21][22] Management of mild to moderate toxicity is symptomatic and supportive. The clinician should correct any significant fluid and electrolyte abnormalities in patients with vomiting or diarrhea. Severe toxicity is not expected following an overdose, which should be managed with symptomatic and supportive treatment.

The management of cromolyn sodium therapy requires a coordinated, interprofessional approach involving physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals to ensure patient-centered care, improved outcomes, and patient safety. Cromolyn sodium is available in various forms and should be administered at regular intervals for optimal efficacy. Clinicians should follow the Global Initiative for Asthma 2023 guidelines, which suggest that while cromolyn is FDA-approved for asthma, it is less effective than other therapies and is not recommended for routine use. Even though these are rare, effective communication between healthcare professionals is crucial in monitoring and managing potential adverse events or hypersensitivity reactions. Nurses and pharmacists must be vigilant in recognizing any adverse events and collaborate with the clinical team to manage them. In a severe reaction, the healthcare team must quickly withdraw cromolyn, administer emergency treatments like epinephrine, oxygen, antihistamines, and corticosteroids, and ensure continuous patient monitoring. A pharmacist should review the patient’s medication records to avoid future complications, while the intensivist may be consulted for hospital observation. After a hypersensitivity event, clinicians must discuss alternative therapies with the patient. This interprofessional coordination enhances patient safety and team performance in cromolyn sodium management for asthma, allergic rhinitis, and mastocytosis.